News & Updates

Transcutaneous neuromodulation at ST36 trumps tibial nerve stimulation in treating constipation

25 Jun 2020

Transcutaneous neuromodulation (TN) at acupoint Zusanli (ST36) appears to be more potent than TN at posterior tibial nerve (PTN) in the treatment of constipation and its related symptoms and rectal sensation, a study has shown.

Transcutaneous neuromodulation at ST36 trumps tibial nerve stimulation in treating constipation

25 Jun 2020

Positive anti-HBc tied to cirrhosis, HCC in NAFLD patients

25 Jun 2020 by

A recent study involving Chinese patients with nonalcoholic fatty liver disease (NAFLD) suggests that positive antihepatitis B core antibody (anti-HBc) is linked to cirrhosis and possibly hepatocellular carcinoma (HCC) and cirrhotic complications.

Positive anti-HBc tied to cirrhosis, HCC in NAFLD patients

25 Jun 2020

Managing GERD in primary care

25 Jun 2020

Gastroesophageal reflux disease (GERD) is a condition which develops when reflux of stomach contents causes troublesome symptoms and/or complications.¹ Audrey Abella speaks with Dr Tan Chi Chiu, gastroenterologist and senior consultant, Gastroenterology & Medicine International at Gleneagles Medical Centre, Singapore, to discuss how GERD can be addressed in the primary care setting.

Managing GERD in primary care

25 Jun 2020

Camrelizumab outwits chemo for oesophageal SCC

25 Jun 2020 by

The anti-PD-1 inhibitor camrelizumab demonstrated superior efficacy over chemotherapy (CT) and a tolerable safety profile for advanced/metastatic oesophageal squamous cell carcinoma (OSCC) in Chinese patients, the ESCORT* trial suggests.

Camrelizumab outwits chemo for oesophageal SCC

25 Jun 2020

10-day more efficient than 14-day nonbismuth quadruple therapy for H. pylori eradication

24 Jun 2020

The 10-day concomitant nonbismuth quadruple regimen for the treatment of Helicobacter pylori infection remains the most efficient strategy as compared with the 14-day therapy, results of a Greek study have shown.

10-day more efficient than 14-day nonbismuth quadruple therapy for H. pylori eradication

24 Jun 2020

Carvedilol plus ivabradine improves LVDD, survival in cirrhosis

23 Jun 2020

The combination of ivabradine and carvedilol improves left ventricular diastolic dysfunction (LVDD), achieves targeted heart rate reduction (THR) more often, and reduces the risk of encephalopathy, leading to improved survival in patients with cirrhosis, reveals a study.

Carvedilol plus ivabradine improves LVDD, survival in cirrhosis

23 Jun 2020

Proton-pump inhibitors up risk of mortality after kidney transplantation

23 Jun 2020 by

Use of proton-pump inhibitors (PPIs) may increase the risk of mortality in kidney transplant recipients (KTRs), independent of potential confounders, reveals a study.

Proton-pump inhibitors up risk of mortality after kidney transplantation

23 Jun 2020

Gut dysbiosis in COVID-19 prompts development of probiotic supplement

23 Jun 2020 by

Patients with coronavirus disease 2019 (COVID-19) have significant gut dysbiosis that persists even after viral clearance and resolution of respiratory symptoms, according to a metagenomic study by the Chinese University of Hong Kong (CUHK). These findings have led to the development of a probiotic supplement expected to be available in a few months.